Andrew J Dannenberg, Jayanta R Chowdhury: Treatment of newborn jaundice. Cornell Research Foundation, Albert Einstein College of Medicine of Yeshiva University a Division of Yeshiva University, December 31, 1996: US05589504 (38 worldwide citation)

Based on the discovery that the human bilirubin/phenol UDP-glucuronosyltransferase ugt1 gene complex contains an electrophile responsive element and the knowledge that the rat NADP(H):quinone reductase gene contains an electrophile responsive element, agents which at a concentration of less than 50 ...

Andrew J Dannenberg, Kotha Subbaramaiah: Treating cancers associated with overexpression of HER-2/neu. Cornell Research Foundation, June 11, 2002: US06403630 (25 worldwide citation)

Cancers associated with overexpression of HER-2/neu are treated with a selective inhibitor of cyclooxygenase-2 as the sole treating agent or said inhibitor in combination regimen with HERCEPTINĀ® and/or standard therapy. Uses include adjuvant therapy for HER-2/neu positive breast cancer and treatment ...

Andrew J Dannenberg: Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors. Cornell Research Foundation, November 26, 2002: US06486203 (8 worldwide citation)

A patient with an inflammatory disease of the head and neck is treated with a therapeutic amount of a selective inhibitor of cyclooxygenase-2 or a cyclooxygenase-2 inhibitor from a natural source. In one embodiment, a patient with a sore throat caused by tonsillitis or pharyngitis is treated with th ...

Andrew J Dannenberg, Kotha Subbaramaiah: Treating cancers associated with overexpression of class I family of receptor tyrosine kinases. September 18, 2001: US06291496 (4 worldwide citation)

Cancer associated with overexpression of class I family of receptor tyrosine kinases, e.g., with overexpresssion of HER-2/neu or overexpression of epidermal growth factor receptor, are treated with strongly binding PPAR&ggr; ligands.

Andrew J Dannenberg, Kotha J Subbaramaiah, David S Pasco: Method of screening agents as candidates for drugs or sources of drugs. Cornell Research Foundation, The University of Mississippi, March 13, 2001: US06200760 (2 worldwide citation)

Cells are transfected with a construct containing transcriptional promoter element(s) that have been implicated in carcinogenesis or inflammation ligated to a reporter gene. Determination of inhibition of activation of said promoter element(s) by putative agent indicates the agent is a candidate as ...

Andrew J Dannenberg, Kotha Subbaramaiah: Treatment of HPV caused diseases. Cornell Research Foundation, Bacon & Thomas PLLC, February 27, 2007: US07183316 (1 worldwide citation)

Human papillomavirus (HPV) protein expression is downregulated in patients infected with HPV by administration of PPARĪ³ ligand, selective inhibitor of cyclooxygenase-2 (COX-2), diaryl heterocycle, inhibitor of HPV protein from a natural source and/or certain non-steroidal anti-inflammatory drugs.

Andrew J Dannenberg: Cyclooxygenase-2 inhibition. Cornell Research Foundation, Bacon & Thomas PLLC, May 9, 2006: US07041694

Selective inhibitors of cyclooxygenase-2 are used to treat liver disease and in combination with anti-viral drugs to treat virus-caused liver disorders. Selective inhibitors of cyclooxygenase-2 which also inhibit the synthesis of cyclooxygenase-2 improve over the efficacy of conventional selective i ...

Andrew J Dannenberg, Amin A Nanji: Treating inflammatory liver disorders by enterally administering a fat-containing diet low in polyunsaturated fats. Cornell Research Foundation, New England Deaconess Hospital, April 22, 1997: US05622991

An enteral diet containing fat in an amount to provide from 20 to 50% of total calories, said fat containing less than 15% polyunsaturated fat (e.g., palm oil or medium chain triglycerides) is administered to mediate amelioration of the inflammation associated with the inflammatory liver, pancreatic ...

Andrew J Dannenberg, George Muller: Inhibition of cyclooxygenase-2 activity. Mathews Collins Shepherd & Mckay Pa, April 22, 2004: US20040077686-A1

The present invention provides new methods for inhibiting the activity of the enzyme cycloxygenase-2 (or COX-2). Inhibitors of COX-2 are known to be useful anti-inflammatory, analgesic and anti-angiogenic agents. The compounds in the present case are heterocyclic substituted 4-aminoglutarimides. Met ...

Andrew J Dannenberg, Kotha Subbaramaiah: Multifunctional COX-2 inhibitors. Bacon & Thomas Pllc, February 10, 2005: US20050031537-A1

Selective inhibitors of COX-2 and selective inhibitors of COX-1 are screened for COX protein independent therapeutic activity. Compounds passing screening testing are indicated for treatment of those having or at risk for cancer, Alzheimer's disease and atherosclerosis.